clinical trial · NCT06532032
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
Janssen Research & Development, LLC·phase2·completed·n = 12
Carcinoma, Non-Small-Cell LungAmivantamabDocetaxel
brief summary
The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and docetaxel combination therapy in participants with metastatic non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination at the selected RP2CD in participants with NSCLC without oncogenic driver mutations with disease progression on platinum-based chemotherapy and immune checkpoint inhibitor, in the Phase 2 (expansion).
started
Jul 23, 2024
primary completion
Apr 14, 2026
completion
May 14, 2026
last updated
Jul 6, 2026
official title
61186372PANSC2003: 61186372PANSC2003 ISA#3 Platform Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol